Effect of plasminogen activators on human recombinant apolipoprotein(a) having the plasminogen activation cleavage site

Biochimica et Biophysica Acta - Protein Structure and Molecular Enzymology

Volumn 1434, Issue 1, 1999, Pages 124-134

  Hervio, Laurence ^a   Brunner, Christoph ^b   Sorell, Luis ^c   Kang, Chantal ^d   Müller, Hans Joachim ^b   Anglés Cano, Eduardo ^d  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^d INSERM   (France)

Author keywords

Activation disulfide loop; Apolipoprotein(a); Arg Val apo(a) mutant; Plasminogen; Plasminogen activation

Indexed keywords

APOLIPOPROTEIN A; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN DOMAIN; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; APOLIPOPROTEINS A; BINDING SITES; DNA, COMPLEMENTARY; ENZYME ACTIVATION; HUMANS; IMMUNOBLOTTING; KRINGLES; LIPOPROTEIN(A); MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PLASMIDS; PLASMINOGEN; PLASMINOGEN ACTIVATORS; RECOMBINANT PROTEINS; SERINE ENDOPEPTIDASES;

EID: 0032754572     PISSN: 01674838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-4838(99)00179-X     Document Type: Article

References (48)

1. McLean J.W., Tomlinson J.E., Kuang W.J., Eaton D.L., Chen E.Y., Fless G.M., Scanu A.M., Lawn R.M. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 330:1987;132-137.
2. Eaton D.L., Fless G.M., Kohr W.J., Xu Q.T., Miller C.G., Lawn R.M., Scanu A.M. Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen. Proc. Natl. Acad. Sci. USA. 84:1987;3224-3228.
3. Utermann G., Weber W. Protein composition of Lp(a) lipoprotein from human plasma. FEBS Lett. 154:1983;357-361.
4. Petersen T.E., Martzen M.R., Ichinose A., Davie E.W. Characterization of the gene for human plasminogen, a key proenzyme in the fibrinolytic system. J. Biol. Chem. 265:1990;6104-6111.
5. Ponting C.P., Marshall J.M., Cederholm-Williams S.A. Plasminogen: a structural review. Blood Coag. Fibrinol. 3:1992;605-614.
6. Robbins K.C., Summaria L., Hsieh B., Shah R.J. The peptide chains of human plasmin. Mechanism of activation of human plasminogen to plasmin. J. Biol. Chem. 242:1967;2333-2342.
7. Miles L.A., Dahlberg C.M., Plescia J., Felez J., Kato K., Plow E.F. Role of cell-surface lysines in plasminogen binding to cells: identification of α-enolase as a candidate plasminogen receptor. Biochemistry. 30:1991;1682-1691.
8. Fleury V., Anglés-Cano E. Characterization of the binding of plasminogen to fibrin surfaces: the role of carboxy-terminal lysines. Biochemistry. 30:1991;7630-7638.
9. Miles L.A., Fless G.M., Levin E.G., Scanu A.M., Plow E.F. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature. 339:1989;301-303.
10. Hajjar K.A., Gavish D., Breslow J.L., Nachman R.L. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 339:1989;303-305.
11. Rhoads G.G., Dahlen G., Berg K., Morton N.E., Dannenberg A.L. Lp(a) lipoprotein as a risk factor for myocardial infarction. J. Am. Med. Assoc. 256:1986;2540-2544.
12. 4057 of apolipoprotein(a) is essential for lipoprotein(a) assembly. Proc. Natl. Acad. Sci. USA. 90:1993;11643-11647.
13. Brunner C., Lobentanz E.M., Pethö-Schramm A., Ernst A., Kang C., Dieplinger H., Müller H.J., Utermann G. The number of identical kringle IV repeats in apolipoprotein(a) affects its processing and secretion by HepG2 cells. J. Biol. Chem. 271:1996;32403-32410.
14. McBride L.J., McCollum C., Davidson S., Efcavitch J.W., Andrus A., Lombardi S. A new, reliable cartridge for the rapid purification of synthetic DNA. Biotechniques. 6:1988;362-367.
15. Felgner P.L., Gadek T.R., Holm M., Roman R., Chan H.W., Wenz M., Northrop J.P., Ringold G.M., Danielsen M. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. USA. 84:1987;7413-7417.
16. Sorell L., Rojas G., Rodriguez M., Ramos C., Torres L., Torres M.B. A sandwich ELISA base on anti-apo(a) and anti-apo B monoclonal antibodies for lipoprotein(a) measurement. Clin. Chim. Acta. 236:1995;59-70.
17. Rouy D., Koschinsky M.L., Fleury V., Chapman J., Anglés-Cano E. Apolipoprotein(a) and plasminogen interactions with fibrin: a study with recombinant apolipoprotein(a) and plasminogen fragments. Biochemistry. 31:1992;6333-6339.
18. Deutsch D., Mertz E.T. Plasminogen purification from human plasma by affinity chromatography. Science. 170:1970;1095-1096.
19. Kazal L.A., Amsel S., Miller O.P., Tocantins L.M. The preparation and some properties of fibrinogen precipitated from human plasma by glycine. Proc. Soc. Exp. Biol. Med. 113:1963;989-994.
20. 308, Lys) does not affect the binding of t-PA and plasminogen to fibrin. Blood Coag. Fibrinol. 4:1993;679-687.
21. Hervio L., Chapman M.J., Thillet J., Loyau S., Anglés-Cano E. Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis? Blood. 82:1993;392-397.
22. Koppert P.W., Koppman J., Haverkate F., Nieuwenhuizen W. Production and characterization of a monoclonal antibody reactive with a specific neoantigenic determinant (comprising Bβ 54-118) in degradation products of fibrin and of fibrinogen. Blood. 68:1986;437-441.
23. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
24. Khyse-Andersen J. Electroblotting of multiple gels: a single apparatus without buffer tank for rapid transfer of protein from polyacrylamide to nitrocellulose. J. Biochem. Biophys. Methods. 10:1984;203-209.
25. Gaussem P., Grailhe P., Anglés-Cano E. Sodium dodecyl sulfate-induced dissociation of complexes between human tissue plasminogen activator and its specific inhibitor. J. Biol. Chem. 268:1993;12150-12155.
26. 2-antiplasmin complexes in plasma. Br. J. Haematol. 92:1996;979-985.
27. Peltz S.W., Hardt T.A., Mangel W.F. Positive regulation of activation of plasminogen by urokinase differences in Km for (Glutamic acid) plasminogen and lysine plasminogen and effect of certain α,ω amino acids. Biochemistry. 21:1982;2798-2804.
28. Davidson D.J., Castellino F.J. The influence of the nature of the asparagine 289-linked oligosaccharide on the activation by urokinase and lysine binding properties of natural and recombinant human plasminogens. J. Clin. Invest. 94:1993;249-254.
29. Neurath H. Proteolytic processing and physiological regulation. T.I.B.S. 14:1989;268-272.
30. Berger A., Schechter I. Mapping the active site of papain with the aid of peptide substrates and inhibitors. Phil. Trans. R. Soc. Lond. B. 257:1970;249-264.
31. Linde V., Nielsen L.S., Foster D.C., Petersen L. Elimination of the Cys558-Cys566 bond in Lys78-plasminogen. Effect on activation and fibrin interaction. Eur. J. Biochem. 251:1998;472-479.
32. Busby S.J., Mulvihill E., Rao D., Kumar A.A., Lioubin P., Heipel M., Sprecher C., Halfpap L., Prunkard D., Gambee J., Foster D.C. Expression of recombinant human plasminogen in mammalian cells is augmented by suppression of plasmin activity. J. Biol. Chem. 266:1991;15286-15292.
33. Dawson K.M., Cook A., Devine J.M., Edwards R.M., Hunter M.G., Raper R.H., Roberts G. Plasminogen mutants activated by thrombin. J. Biol. Chem. 269:1994;15989-15992.
34. Gabel B.R., Koschinsky M.L. Analysis of the proteolytic activity of a recombinant form of apolipoprotein(a). Biochemistry. 3:1995;15777-15784.
35. Sangrar W., Gabel B.R., Boffa M.B., Walker J.B., Hancock M.A., Marcovina S.M., Horrevoets A.J.G., Nesheim M.E., Koschinsky M.L. The solution phase interaction between lipoprotein(a) and plasminogen inhibits the binding of plasminogen to a plasmin-modified fibrinogen surface. Biochemistry. 36:1997;10353-10363.
36. Ganu V.S., Shaw E. Synthesis and properties of cyclic peptides containing the activation site of plasminogen. Int. J. Pept. Protein Res. 20:1982;421-428.
37. Madison E., Coombs G.S., Corey D.R. Substrate specificity of tissue type plasminogen activator. J. Biol. Chem. 270:1995;7558-7562.
38. Renatus M., Bode W., Huber R., Stürzebecher J., Prasa D., Fischer S., Kohnert U., Stubbs M.T. Structural mapping of the active site specificity determinants of human tissue-type plasminogen activator. Implications for the design of low molecular weight substrates and inhibitors. J. Biol. Chem. 272:1997;21713-21719.
39. Coombs G.S., Dang A.T., Madison E.L., Corey D.R. Distinct mechanisms contribute to stringent substrate specificity of tissue-type plasminogen activator. J. Biol. Chem. 271:1996;4461-4467.
40. Ke S.H., Coombs G.S., Tachias K., Corey D.R., Madison E.L. Optimal subsite occupancy and design of a selective inhibitor of urokinase. J. Biol. Chem. 272:1997;20456-20462.
41. Ke S.H., Coombs G.S., Tachias K., Navre M., Corey D.R., Madison E.L. Distinguishing the specificities of closely related proteases. Role of P3 in substrate and inhibitor discrimination between tissue-type plasminogen activator and urokinase. J. Biol. Chem. 272:1997;16603-16609.
42. Stack M.S., Pizzo S.V., Gonzalez-Gronow M. Effect of desialylation on the biological properties of human plasminogen. Biochem. J. 284:1992;81-86.
43. Gonzalez-Gronow M., Edelberg J.M., Pizzo S.V. Further characterization of the cellular plasminogen binding site evidence that plasminogen 2 and lipoprotein(a) compete for the same site. Biochemistry. 28:1989;2374-2377.
44. Wittwer A.J., Howard S.C. Glycosylation at Asn-184 inhibits the conversion of single-chain to two-chain tissue-type plasminogen activator by plasmin. Biochemistry. 29:1990;4175-4180.
45. Ratzin K.H., Armstrong V.W., Niehaus M., Hilschmann N., Seidel D. Structural relationship of an apolipoprotein(a) phenotype (570 kDa) to plasminogen: homologous kringle domains are linked by carbohydrate-rich regions. Biol. Chem. Hoppe-Seyler. 368:1987;1533-1544.
46. Koschinsky M.L., Tomlinson J.E., Zioncheck T.F., Schartz K., Eaton D., Lawn R.M. Apolipoprotein(a) expression and characterization of a recombinant form of the protein in mammalian cells. Biochemistry. 3:1991;5044-5051.
47. Miyata T., Iwanaga S., Sakata Y., Aoki N. Plasminogen Tochigi: inactive plasmin resulting from replacement of alanine-600 by threonine in the active site. Proc. Natl. Acad. Sci. USA. 79:1982;6132-6136.
48. Ichinose A., Espling E.S., Takamatsu J., Saito H., Shinmyozu K., Maruyama I. Two types of abnormal genes for plasminogen in families with a predisposition for thrombosis. Proc. Natl. Acad. Sci. USA. 88:1991;115-119.